What this band has actually done:
stocks scoring 25–45
beat the S&P 500 over the next three months
45.3%
of the time, across 39,662 cases
since 2015.
That is below a coin flip — and so is every other band, because the
median stock loses to a cap-weighted index.
How we measured this
Hedge funds
45
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$2.2B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGM
About ADMA BIOLOGICS INC
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure…
Who's behind the signal
Every informed buyer we can see on ADMA, across all three feeds.
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
ADMA BIOLOGICS INC isn't in the top-10 model right now, but 9 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
9
Investors
1
New positions
3
Increasing
5
Decreasing
0
Unchanged
Price History
Loading price data...
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
How much of each investor's portfolio is allocated to ADMA BIOLOGICS INC
Insider Trading (Form 4)
Recent trades by company officers and directors — filed within 2 days of each trade
Neutral
Sentiment
1
Buys
0
Sells
Date
Insider
Title
Action
Shares
Price
Value
2026-05-27
Grossman Jerrold B
Insider
BUY
6,400
$7.91
$50,624
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell ADMA BIOLOGICS INC or any security.